Association Between The Consumption Of Fluticasone Corticosteroid Inhaler and Exacerbation In Chronic Obstructive Pulmonary Disease Patients In Abdul Moeloek Hospital from 2015-2017
DOI:
https://doi.org/10.53089/medula.v10i3.169Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease with irreversible condition. One of the treatment
using fluticasone inhaled corticosteroids shows a significant improvement in lung function, reducing symptoms and
reducing exacerbations. The purpose of this study was to determine the relationship of fluticasone corticosteroid inhalation
with the incidence of exacerbations in COPD patients at Abdul Moeloek Regional Hospital in the period 2015-2017 Lampung
Province. This study was an observational study that used secondary data (medical records) of 102 patients who were
analyzed the type of the drug they used with the occurrence of exacerbations they experienced. The results of the analysis
in this study showed a significant correlation between the use of fluticasone inhaled corticosteroids and the exacerbations
in COPD patients at Abdul Moeloek Hospital in 2015-2017 with a p value of 0.049 (p <0.05).
References
Perhimpunan Dokter Paru Indonesia.
Penyakit Paru Obstruktif Kronik
(PPOK). Pedoman Diagnosis &
Penatalaksanaan di Indonesia.
Perhimpunan Dokter Paru Indonesia.
Barnett, Margaret. 2006. Chronic
Obstructive Pulmonary
Disease.Chichester : John Wiley & Sons,
Ltd.
Supriyadi, Megantara. 2013. Faktor
Genetik Penyakit Paru Obstuksi Kronik.
Jakarta: Majalah Kedokteran Universitas
Indonesia Vol 40 No 8.
Riyanto BS, Heni RW, Barmawi H. 2014.
Ilmu Penyakit Dalam. Jakarta : Internal
Publishing Jilid I edisi VI, hal 204.
Han MK, Lazarus SC. 2016.COPD: Clinical
Diagnosis and Management. In :
Broaddus, V.C, et al, (Eds.). Textbook of
Respiratory Medicine. Ed, 6th, Canada :
Elsevier Inc.
Williams, Dennis M., Bourdet, Sharya V.
Chronic Obstructive Pulmonary
Disease.In : DiPiro, J, et al, (Eds).
Pharmacotherapy A Pathophysiologic
Approach seventh edition. New York: Mc
Graw-Hill. pp. 528-550.
GOLD. 2015.Pocked Guide To COPD
Diagnosis, Management, and Prevention.
USA : Global Initiative for Chronic
Obstructive Lung Disease, Inc.
Siswandono dan Soekardjo B.2008.Kimia
Medisinal Edisi ke-2. Surabaya: Airlangga
University Press, hal 423-434.
Akkermans RP, Biermans M, Robberts B,
Ter GJ, Jacob A, Van WC et al. 2014.
COPD prognosis in relation to diagnostic
criteria for airflow obstruction in
smokers.Radboud University Medical
Center. European Respiratory Journal
(1): 54-63
Prazasta RP. 2015. Penilaian Tingkat
Risiko dan Faktor-faktor yang
Berhubungan dengan Penyakit Paru
Obstruktif Kronik pada Masyarakat
Binaan KPKM Buaran FKIK UIN Syarif
Hidayatullah Tahun 2015. Jakarta: UIN
Syarif Hidayatullah
Tashkin D, Strange C. 2018. Inhaled
corticosteroids for chronic obstructive
pulmonary disease: what is their role in
therapy. International Journal of COPD;
-2601
Calverley PM, Anderson JA, Celli B,
Ferguson GT, Jenkins C, Jones PW, et al.
Salmeterol and fluticasone
propionate and survival in chronic
obstructive pulmonary disease.N Engl J
Med 2007; 356:775–789.
Lukito DB, Permana p. 2017. Penyakit
Paru Obstruksi Kronis Eksaserbasi Akut.
Fakultas Kedokteran Universitas
Udayana.
Wan ES, DeMeo DL, Hersh CP, Shapiro
SD, Rosiello RA, Sama SR, et al. 2011.
Clinical predictors of frequent
exacerbations in subjects with severe
chronic obstructive pulmonary disease
(COPD). Respir Med;105(4):588- 594.
Sin DD, Paul Man SF, Marciniuk DD, Ford
G, FitzGerald M, Wong E et al. The effect
of fluticasone with or without salmeterol
on systemic biomarkers of inflammation
in Chronic Obstructive Pulmonary
Disease. Am J Respir Crit Care Med 2008;
:1207-1214
Yawn BP, Raphiou I, Hurley JS, Dalal AA.
The role of fluticasone
propionate/salmeterol combination therapy in preventing exacerbations of
COPD. International Journal Chronic
Obstruct Pulmonary Disease; 5: 165–178.
Martinez FJ, Hastie AT. Curtis JL, et al.
Association of sputum and blood
eosinophil concentrations with clinical
measures of COPD severity: an analysis of
the SPIROMICS cohort. Lancet Respir
Med; 5(12):956–967.
Lipson, Barnhart, Brealey, Brooks, Criner,
Day NC et al. 2018. Once-Daily SingleInhaler
Triple versus Dual Therapy in
Patients with COPD. The New England
Journal of Medicine 378:1671-1680
Dransfield, Bourbeau, Jones, Hanania,
Mahler, Vestboet al. 2013.Once-daily
inhaled fluticasone furoate and vilanterol
versus vilanterol only for prevention of
exacerbations of COPD: two replicate
double-blind, parallel-group, randomised
controlled trials. The Lancet Respiratory
Medicine;1(3), 210–223.
Verhoeven GT, Hegmans JP, Mulder PG,
Bogaard JM, Hoogsteden HC, Prins JB.
Effects of fluticasone propionate in
COPD patients with bronchial
hyperresponsiveness. Thorax. 57(8): 694–
Rycroft C, Heyes, Lanza, Karin. 2012.
Epidemiologgy of Chronic Obstructive
Pulmonary Disease: a Literature Review.
International Journal of Chronic
Obstructive Pulmonary Disease; 457.
Rahmatika A. 2009. Karakteristik
penderita penyakit paru obstruktif kronik
yang di rawat inap di RSUD Aceh Tamiang
tahun 2007-2008. Medan: Universitas
Sumatra Utara
Departemen Kesehatan R.I. Direktorat
Jenderal Pengendalian Penyakit dan
Penyehatan Lingkungan Direktorat
Pengendalian Penyakit menular. 2008.
Pengendalian Penyakit Paru Obstruktif
Kronik (PPOK).Departemen Kesehatan R.I.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 MEDULA
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
